Activity of zinc oxide and zinc borate nanoparticles against resistant bacteria in an experimental lung cancer model.

Abstract

Recent research indicates a prevalence of typical lung infections, such as pneumonia, in lung cancer patients. Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii stand out as antibiotic-resistant pathogens. Given this, there is a growing interest in alternative therapeutic avenues. Boron and zinc derivatives exhibit antimicrobial, antiviral, and antifungal properties. This research aimed to establish the effectiveness of ZnO and ZB NPs in combating bacterial infections in lung cancer cell lines. Initially, this study determined the minimal inhibitory concentration (MIC) and fractional inhibitory concentration (FIC) of zinc oxide nanoparticles (ZnO NPs) and zinc borate (ZB) on chosen benchmark strains. Subsequent steps involved gauging treatment success through a lung cancer-bacteria combined culture and immunohistochemical analysis. The inhibitory impact of ZnO NPs on bacteria was charted as follows: 0.97µg/mL for K. pneumoniae 700603, 1.95µg/mL for P. aeruginosa 27853, and 7.81µg/mL for Acinetobacter baumannii 19,606. In comparison, the antibacterial influence of zinc borate was measured as 7.81µg/mL for Klebsiella pneumoniae 700603 and 500µg/mL for both P. aeruginosa 27853 and A.baumannii 19606. After 24h, the cytotoxicity of ZnO NPs and ZB was analyzed using the MTT technique. The lowest cell viability was marked in the 500µg/mL ZB NPs group, with a viability rate of 48.83% (P < 0.001). However, marked deviations appeared at ZB concentrations of 61.5µg/mL (P < 0.05) and ZnO NPs at 125µg/mL. A synergistic microbial inhibitory effect was observed when ZnO NP and ZB were combined against the bacteria under investigation.